Bluecrest Wellness Cancer screening

Lung Cancer (EarlyCDT)

A blood test measuring antibody response to seven proteins linked to lung cancer cells, reported as low, moderate or high risk.

Sample
Blood
Collection
Venous draw at local venue
Results in
3–8 days
Biomarkers
1
Doctor reviewed
No
Tests for
  • EarlyCDT-Lung autoantibody panel

Test specifications

Provider
Bluecrest Wellness
Sample type
blood
Collection method
venous draw at local venue
Turnaround time
3–8 days
Biomarkers tested
1
At-home test
No
Doctor reviewed
No
Gender focus
Both

What's tested

1 biomarker as listed by Bluecrest Wellness.

  • EarlyCDT-Lung autoantibody panel

About this test

The Lung Cancer (EarlyCDT) test measures your immune response, specifically autoantibodies, to seven proteins produced by lung cancer cells. Bluecrest reports the result as low, moderate or high risk, and recommends further investigation with your GP if the result comes back moderate or high.

As a single-panel test, it places in the 32nd percentile for clinical depth among the cancer screening tests we track. Price is the bigger outlier: at £299, it costs around four times the £75 median for the 19 similarly sized cancer screening tests in our data.

Clarity scores well, with a detailed description, the marker named, sample type and turnaround all stated. Results and follow-up score lower here than Bluecrest's Female and Male Cancer Risk packages, because this test is not reviewed by a doctor as standard, despite testing for a serious condition.

Who is it for?

This may suit you if you have specific risk factors for lung cancer, such as a smoking history, and want an autoantibody-based check in addition to standard screening. Because results are not doctor-reviewed as standard and the test is priced well above other cancer screening options in our data, discuss with your GP whether a different pathway might suit your situation better before booking privately. A moderate or high result on its own is not a diagnosis and needs further investigation.

How it works

This is a blood test collected by venous draw at a local Bluecrest venue. Your sample is analysed for antibody response to seven lung cancer-related proteins, and results are typically returned in around 3 to 8 days as a low, moderate or high risk classification. There is no doctor review included as standard; Bluecrest recommends seeing your GP if the result is moderate or high.

Pros & cons

Pros

  • Reports a clear low, moderate or high risk classification rather than raw numbers alone.
  • Can be added as an individual test to any existing Bluecrest package.
  • Listing publishes a detailed description, the marker named and a stated turnaround.

Cons

  • At £299, it costs around four times the £75 median for the cancer screening tests we track.
  • No doctor review is included as standard, despite testing for a serious condition.
  • A moderate or high result is not diagnostic and needs GP follow-up regardless.

Our editorial score

Compare Health Test Score Priciest cancer test here, well above the category median
Editorial confidence: 10.0/10

This EarlyCDT test costs £299, four times the £75 median for the cancer screening tests we track. It measures your antibody response to seven lung cancer-related proteins and reports a low, moderate or high risk result, but unlike Bluecrest's cancer risk packages, there is no doctor review included as standard.

Score breakdown

  • Clarity and documentation 9.0/10

    The listing publishes a detailed description, the full biomarker list, a stated turnaround, clear collection options, the sample type; it does not state what the report looks like.

  • Clinical depth 6.4/10

    1 biomarkers, placing it in the 32nd percentile of cancer screening tests we track.

  • Collection convenience 3.0/10

    Requires a venous draw at a clinic; results in around 8 days, slower than similar tests.

  • Results and follow-up 3.0/10

    Results are not doctor-reviewed and no consultation is included; the provider does not describe the report format.

  • Trust signals 9.5/10

    Trustpilot 4.7 from 6,787 reviews; accredited lab (UKAS ISO 15189 own lab); CQC registered; trading 14+ years.

  • Value for money 2.0/10

    £299.00 against a median of £75.00 for the 19 similarly sized cancer screening tests we track (+299%).

Calculated 13 September 2026 from the facts we hold about this test and provider, using our published scoring formula. Scores are not hand-edited.

More in Cancer screening

View all →
Selph

qFIT Bowel Cancer Screening Test

Priced close to the FIT test group median

A stool test using the qFIT method to measure blood in a stool sample, giving a numerical result rather than a simple positive or negative. Suited to adults wanting to check a common early indicator of possible bowel cancer risk.

  • At-home test
8.1 / 10
£59.00
Full review →